To develop an iPSC-derived CAR-T therapy for solid tumours, we recently generated CAR-expressing iPSC-derived NK/innate lymphocyte cells (ILCs) that target glypican3 (GPC3)-expressing tumours15, such as hepatocellular carcinoma and ovarian clear cell carcinoma. This evidence concerns the gene GPC3 and hepatocellular carcinoma.